Compare Crispr Therapeutics AG (CRSP) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nokia Corp — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 11.7× Crispr Therapeutics AG's market cap, and Nokia Corp pays a 1.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nokia Corp for 66 Days on average.
| CRSP | NOK | |
|---|---|---|
Market Cap | $4.88B | $56.99B |
Volume | 2,861,747 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $74.92 | $16.83 |
52-Week Low | $44.34 | $5.18 |
Typical Hold Time | 77 Days | 66 Days |
Enterprise Value | $3.30B | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Nokia (NOK) trades at $10.14, down 4.52% today, amid bearish technical signals but strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 75.09 but improving revenue trends, with 2026 revenue projected at $20.4B. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Cash flow volatility remains a concern with negative net cash flow in 2025 and 2026.
The outlook is cautiously optimistic with a consensus price target of $17.50 representing 73% upside potential. Key opportunities include AI infrastructure demand and expanding partnerships, while risks involve cash flow instability and competitive pressures in telecom equipment. Analyst sentiment is strongly bullish with 62% buy ratings, though technical indicators suggest near-term weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
